Ignite Creation Date:
2024-10-26 @ 3:38 PM
Last Modification Date:
2024-10-26 @ 3:38 PM
Study NCT ID:
NCT06569095
Status:
NOT_YET_RECRUITING
Last Update Posted:
None
First Post:
2024-07-15
Brief Title:
Measurable Residual Disease Assessment of Cells With Leukemic Stem Cells Associated Phenotype in Patients With Myelodysplastic Syndrome a Multi-center Prospective Clinical Study
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Measurable Residual Disease Assessment of Cells With Leukemic Stem Cells Associated Phenotype in Patients With Myelodysplastic Syndrome a Multi-center Prospective Clinical Study
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-08
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
At present multiparameter flow cytometry MFC and polymerase chain reaction PCR are recommended for measurable residual disease MRD monitoring in China Due to the lack of fusion genes detectable by PCR in some patients MFC is the most commonly used MRD monitoring method Both leukemia-associated immunophenotype LAIP and different from normal DfN immunophenotype in traditional MFC methods have false positives and false negatives Therefore a new MFC-MRD evaluation method is needed to address these issues Some studies have reported that using MFC to detect MRD may improve the sensitivity and predictive value of MRD Our research aims to observe whether bone marrowBM and peripheral bloodPB MRD monitoring can predict the prognosis of Myelodysplastic syndromes MDS patients
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None